Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12749725)

  • 1. Implications of genetic testing in the management of colorectal cancer.
    Stoehlmacher J; Lenz HJ
    Am J Pharmacogenomics; 2003; 3(2):73-88. PubMed ID: 12749725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored chemotherapy for colorectal cancer: a new approach to therapy.
    Iqbal S; Stoehlmacher J; Lenz HJ
    Cancer Invest; 2004; 22(5):762-73. PubMed ID: 15581057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
    Shimamoto Y; Nukatsuka M; Takechi T; Fukushima M
    Int J Mol Med; 2016 Feb; 37(2):319-28. PubMed ID: 26676887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and biomarkers in colorectal cancer.
    Strimpakos AS; Syrigos KN; Saif MW
    Pharmacogenomics J; 2009 Jun; 9(3):147-60. PubMed ID: 19381163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives.
    Fogli S; Caraglia M
    Expert Opin Pharmacother; 2009 May; 10(7):1095-108. PubMed ID: 19405786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of colorectal cancer.
    Marsh S
    Expert Opin Pharmacother; 2005 Dec; 6(15):2607-16. PubMed ID: 16316300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
    Di Francia R; De Lucia L; Di Paolo M; Di Martino S; Del Pup L; De Monaco A; Lleshi A; Berretta M
    Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4443-54. PubMed ID: 26636535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy.
    Russo A; Corsale S; Cammareri P; Agnese V; Cascio S; Di Fede G; Macaluso M; Bazan V
    J Cell Physiol; 2005 Sep; 204(3):742-9. PubMed ID: 15828025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic aspects in treatment of colorectal cancer--an update.
    Stoehlmacher J; Goekkurt E; Lenz HJ
    Pharmacogenomics; 2003 Nov; 4(6):767-77. PubMed ID: 14596640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
    Koopman M; Venderbosch S; Nagtegaal ID; van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1935-49. PubMed ID: 19473832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes.
    Gustavsson B; Kaiser C; Carlsson G; Wettergren Y; Odin E; Lindskog EB; Niyikiza C; Ma D
    Int J Cancer; 2009 Mar; 124(5):1220-6. PubMed ID: 19051292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.
    Bandrés E; Zárate R; Ramirez N; Abajo A; Bitarte N; Garíia-Foncillas J
    World J Gastroenterol; 2007 Nov; 13(44):5888-901. PubMed ID: 17990354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
    Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?
    O'Connell MJ; Schaid DJ; Ganju V; Cunningham J; Kovach JS; Thibodeau SN
    Cancer; 1992 Sep; 70(6 Suppl):1732-9. PubMed ID: 1516028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer].
    Milano G
    Rev Prat; 2008 May; 58(10):1056-9. PubMed ID: 18652401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.
    Donnelly JG
    Ther Drug Monit; 2004 Apr; 26(2):231-5. PubMed ID: 15228171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.
    O'Dwyer PJ; Catalano RB
    J Clin Oncol; 2006 Oct; 24(28):4534-8. PubMed ID: 17008691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.